virus-like particles (VLPs) were determined by enzyme-linked immunosorbent assay in serum samples collected from children who presented to the hospital because of acute norovirus gastroenteritis in 2009-2011. The blocking activity of the antibodies was tested in a surrogate neutralization assay.
Noroviruses (NoVs) are, after rotaviruses, the second most common causative agents of acute gastroenteritis in children [1] [2] [3] [4] [5] . In countries with a national rotavirus vaccination program, such as the United States and Finland, NoVs have become the most common cause of acute gastroenteritis in hospitalized children as the incidence of rotavirus infection has decreased [6, 7] . In Finland, the proportion of NoV-associated gastroenteritis cases among all acute gastroenteritis cases seen in a major hospital increased from 24% during the 2 years before introduction of rotavirus vaccine to 37% during the 2 years after the introduction of rotavirus vaccine, owing to a decreased number of rotavirus-associated gastroenteritis episodes during the latter period [7] . Consequently, research and development efforts are underway to create a vaccine that can protect against NoV infection [8, 9] .
Most NoV infections in humans are caused by NoVs belonging to genogroup II (GII), with a minority caused by GI. According to recently proposed classification, there are currently 9 GI and 22 GII capsid genotypes [10] . Genotype GII-4 has caused most of the NoV outbreaks and sporadic infections for 2 decades [11, 12] . A novel predominant GII-4 variant emerges every 2-3 years [13, 14] and several mechanisms have been proposed to drive GII-4 escape from herd immunity [13, [15] [16] [17] [18] [19] [20] . GII-4 NoV variants have maintained dominance since 1990's in Finland as well [3] . The predominant NoV strain during 2009-2011 in Finland and globally was GII-4 New Orleans (NO), even if characteristic genetic diversity coexisted [3, 21] .
NoV incidence is the highest in children <2 years of age [6, 22] , who also have the least NoV-specific antibodies [22] [23] [24] [25] . The prevalence of antibodies to NoV increases rapidly before the age of 5 years, when the majority of the population has been exposed to NoV [22, 24, 26] .
Correlates of protection from NoV infection and disease are still poorly understood [27] [28] [29] . In adults, both genotypespecific and cross-reactive antibodies, especially within the same genogroup, are generated after NoV infection [30, 31] . Several prospective epidemiological studies have suggested that high NoV genotype-specific serum antibody levels correlate with protection from infection in children [22, 23, 32, 33] . On the other hand, serological studies have demonstrated that even robust and broad genotype-specific preexisting IgG antibodies found in adult sera have not conferred protection from NoV infection [34] [35] [36] . More recently, the serum IgG antibodies that block binding of NoV VLPs to histo-blood group antigen (HBGA) ligands on the cell surface have been suggested to correlate with protection against NoV infection [19, 20, 22, 36] .
To gain insight into the epidemiologic patterns of sporadic NoV infections and to determine the significance of preexisting immunity to NoVs, we analyzed NoV-specific IgG antibody levels and blocking potential in acute serum from children presenting with NoV-associated acute gastroenteritis. Our results suggest that the magnitude and antibody blockade of GII-4 NO strain-specific serum IgG negatively correlate with susceptibility to GII-4 NO infection.
MATERIALS AND METHODS

Study Material
A total of 666 children <15 years old presenting with gastroenteritis were enrolled in a prospective etiological study at Tampere University Hospital [3, 7] Eligible subjects were ≤15 years of age who were either visiting the hospital outpatient clinic or admitted to a hospital ward with acute gastroenteritis. The study protocol and informed consent forms had been approved by the Ethics Committee of the Pirkanmaa Hospital District, and informed consent was given by the parents or guardians of eligible children before samples were collected. NoV infection was confirmed in stool samples by reverse-transcription polymerase chain reaction as previously reported [3, 7] . Acute-phase serum samples were collected within a week after disease onset, and convalescent-phase serum samples were obtained 2-6 weeks after the onset of disease. The sera were stored at −20°C before analysis.
Antigens
Five NoV capsid-derived virus-like particles (VLPs) belonging to GI and GII were used as coating antigens in enzyme-linked immunosorbent assays (ELISAs). The VLPs were produced using a baculovirus-insect cell expression system and purified by gradient ultracentrifugation as previously described [8, 37] . The selected genotypes were GII-4-2010 NO (GenBank accession number GU445325), GII-4-1999 (AF080551), GII-12-1998 (AJ277618), GI-1-2001 (AY502016.1), and GI-3-2002 (AF414403). Protein concentration, purity, integrity, morphology, and in vitro antigenicity were determined as described earlier [8, 37, 38] .
Serum Antibody ELISA Sera were tested for total IgG against NoV VLPs in ELISA as previously described [8, 22, 39] , with some modifications. In brief, 96-well half-area polystyrene plates (Corning, Corning, NY) were coated with 0.5 µg/mL of GII-4 NO, GII-4-1999, GII-12, GI-3, or GI-1 VLPs in phosphate-buffered saline. The serum samples were added to the plates blocked with 5% milk at 2-fold serial dilutions, starting at 1:100. One known positive human serum sample and 1 known negative human serum sample were included on every plate as controls. Bound antibody was detected with horseradish peroxidase-conjugated anti-human IgG (Invitrogen), followed by reaction with 0.4 mg/mL o-phenylenediamine dihydrochloride substrate (FAST-OPD, Sigma-Aldrich). The OD was measured in a microplate reader (Victor 2 1420, PerkinElmer) at 490 nm. Background signal from the blank wells (ie, wells without serum) was subtracted from all of the OD readings on a plate. A positive reaction was defined as an OD that was 3 standard deviations above the mean OD for negative control serum and at least 0.200. End point titers were defined as the reciprocal of the final serum dilution giving a mean OD 490 nm of ≥0.200 after background subtraction. Seroconversion was considered to have occurred if the convalescent-phase serum sample had a ≥4-fold greater titer than the acute-phase serum sample. Antibody values were log transformed to establish geometric mean titers (GMTs) for analysis.
Serum Antibody Blocking Assay
Blocking of GII-4 NO-2010 and GII-4-1999 VLPs binding to HBGA carbohydrates in secretor-positive human saliva type A was performed as previously described for mouse antisera with slight modifications [40] . In brief, 2-fold serial dilutions of sera ranging from 1:25 to 1:204 800 were pre-incubated with 0.1 µg/ mL of GII-4 NO or GII-4-1999 VLPs at 37°C for 1 hour, followed by a 1.5-hour incubation at 37°C on 96-well plate coated with human saliva type A. VLP binding was detected by GII-4 NO-or GII-4-1999-specific mouse sera (a 1:800 dilution) followed by goat anti-mouse IgG-horseradish peroxidase (Sigma) and Sigma Fast-OPD substrate. The blocking index was defined as the percentage of VLPs binding in the presence of serum, compared with the maximum binding in the absence of serum, using the following equation: 100 -[OD for wells with serum/OD for wells without serum] × 100. The titer at which 90% of binding was blocked (BT 90 ) was determined for each sample, defined as the reciprocal of the lowest serum dilution that blocked at least 90% of VLPs binding to HBGA. An arbitrary BT 90 of 12.5 was assigned to BT 90 of <25 for statistical analyses.
Statistical Analyses
The Fisher exact test was used to determine the statistical difference in antibody quantity between the group infected with GII-4 NO and the group infected with other NoV GII genotypes, as well as between different age groups. The Spearman rank correlation coefficient was used to examine the differences between preexisting antibody titer, blocking titer BT 90 and infection acquired. Statistical analyses were performed using IBM SPSS Statistics (SPSS, Chicago, IL) version 20.0. Statistical significance was defined as a P value of <.05.
RESULTS
NoV Infection and Association With Age
All age groups were represented among the enrolled patients with gastroenteritis. The proportion of young children (age, <2 years) was slightly higher among the NoV-positive cases (75.6%), compared with all enrolled patients with gastroenteritis Figure 1 . Norovirus (NoV) infections and age distribution. A, Distribution of enrolled subjects presenting with gastroenteritis (GE) of any cause and those presenting with NoV-associated gastroenteritis (NoV GE), stratified according to age group. B, The number of subjects, by age, presenting with each infecting NoV genotype detected in the study population. Abbreviations: GII, genogroup II; NO, New Orleans. , and >2 years (n = 11). B, Genotype-specific IgG titers for children with and children without NoV genogroup II (GII)-4 New Orleans (NO) infection. Bars represent log 10 geometric mean titers with 95% confidence intervals. Statistical differences between any 2 experimental groups were determined by a Fisher exact test, and a P value of ≤.05 was considered to be statistically significant.
(58%; Figure 1A ). The age distribution in the group of NoVpositive patients with acute serum samples collected was similar to that in the group of all NoV-positives patients (data not shown).
Of 43 children presenting with acute gastroenteritis due to NoV, 27 (62.8%) experienced GII-4 NO infection, whereas 16 (37.2%) were infected with other G11 genotypes ( Figure 1B ).
Preexisting NoV Genotype-Specific Antibody Responses
Preexisting serum IgG levels against 5 NoV genotypes-GII-4-1999, GII-4 NO-2010, GII-12-1998, GI Figure 2A . Significant differences between different age groups for GII-4 NO-and GII-4-1999-specific antibody titers were observed (P < .05). Overall, 55.6% of <1-year-old children and 35.7% of 1-2-year-old children had a low preexisting serum end point titer (≤800) against all tested NoV genotypes, whereas all of the children >2 years of age had high NoV-specific antibody titers (end point titer, ≥3200) at least against one of the NoV genotypes (data not shown).
Children infected with GII-4 NO had significantly lower levels of preexisting GII-4 NO-specific IgG, compared with children infected with other GII genotypes (P < .05; Figure 2B ). Acute sera from all GII-4 NO-infected patients recognized genotype GII-4 NO VLP but at a low titer (GMT, 958). On the contrary, patients infected with non-GII-4 NO had significantly higher preexisting GII-4 NO-specific titers (GMT, 13958). Congruently, when ancestor GII-4-1999 VLP-specific reactivity was analyzed, the trend was similar to the GII-4 NO VLP seroresponses ( Figure 2B ), with patients with GII-4 NO infection having a lower response than patients without GII-4 NO infection (GMT, 910 vs 5154; P = .061). In general, moderate serum levels of IgG antibody to GII-12, GI-1, and GI-3 NoV VLPs were detected (GMT, < 1745 for all), and no significant differences were observed between children with and those without GII-4 NO infection (P > .3; Figure 2B ).
NoV VLP type-specific IgG antibody titration curves for each patient's acute sera are shown in Figure 3A -E. A majority of GII-4 NO-infected patients (74.1%) had a GII-4 NO-specific end point titer of ≤1600 ( Figure 3A) , and all end point titers were ≤12 800. Corresponding low end point titers were determined for GII-4-1999 ( Figure 3B ), GII-12 ( Figure 3C ), GI-1 ( Figure 3D) , and GI-3 ( Figure 3E ) in GII-4 NO-infected patients' sera. To the contrary, 56.3% of patients without GII-4 NO infection had high GII-4 NO-specific end point titers (≥51 200; Figure 3A) , and 12.5% had high GII-4-1999-specific titers ( Figure 3B) . No difference in GII-12, GI-1, and GI-3 specific titers in acute-phase sera was detected between children with and those without GII-4 NO infection ( Figure 3C-E ) .
Acute-Phase Serum Blocking Antibodies
Individual acute serum samples were also analyzed for the potential to block the binding of GII-4 NO VLP to saliva type A, and blocking activity was compared to preexisting GII-4 NOspecific IgG end point titers (Figure 4) . A positive correlation was detected between the antibody levels and BT 90 (Spearman rank correlation coefficient [r], 0.477; P < .01). All GII-4 NOinfected children had a GII-4 NO-specific end point titer of <12 800 and a BT 90 of ≤100, and 61.9% of these children had a BT 90 of <25. On the contrary, 56.3% of children without GII-4 NO infection had a high preexisting GII-4 NO-specific IgG end point titer (>51 200) and a BT 90 of >200.
Convalescent-Phase Sera Antibody Responses
Paired sera from 6 patients infected with GII-4 NO were tested for seroconversion against each of the NoV VLPs (Table 1) . Acute-phase serum samples were collected 2-6 days (median, 3.5 days) and convalescent-phase serum samples 18-29 days (median, 26 days) after onset of acute gastroenteritis. All patients seroconverted to GII-4 NO, 4 seroconverted to GII-4-1999, 1 seroconverted to GII-12, and 0 seroconverted to GI-1 and GI-3. GII-4 NO infections induced high type-specific serum IgG responses, as well as a cross-reactive response to the GII-4-1999 strain. Serum antibody levels against more-distinct GI-1 and GI-3 NoV VLPs remained similar after infection, indicating low cross-reactivity between GI and GII NoVs. Blocking of GII-4 NO and GII-4-1999 VLP binding to saliva type A by the 6 convalescent-phase serum samples was also tested and compared to genotype-specific IgG titers ( Figure 5A-F) . The I  II  I  II  I  II  I  II  I  II   1  15  26  800  204 800   b   400  12 800   b   800  1600  400  400  200  400   2  8  25  200  204 800   b   200  3200   b   400  400  100  100  200  400   3  18  26  1600  204 800   b   1600  3200  3200  1600  800  400  800  400  4  3  18  800  3200   b   6400  6400  1600  800  3200  1600  3200  3200   5  16  26  200  409 . Correlation between the norovirus genogroup II (GII-4) New Orleans-specific titer at which 90% of binding was blocked (BT 90 ) and the serum immunoglobulin G end point titer among study subjects.
GII-4 NO-specific blocking index of each subject increased along with the IgG titer following GII-4 NO infection. The youngest, a 3-month-old patient ( Figure 5E ), had a weaker IgG response after infection, compared with other patients (Figure 5A-D and 5F ), but both seroconversion and a 16-fold increase in blocking titer were observed (acute-phase serum BT 90 , 12.5; convalescent-phase serum BT 90 , 200). The period between the onset of the disease and the collection of convalescent-phase serum specimen was 7-11 days shorter for this patient than for the others (Table 1) . However, despite seroconversion to GII-4-1999 in 4 subjects, no corresponding increase in GII-4-1999-specific blocking titer was observed (data not shown).
DISCUSSION
In the present study, we determined preexisting NoV-specific IgG antibody levels against 5 different NoV genotypes-GII-4-1999, GII-4-2010 NO, GII-12-1998, GI-1-2002, and GI-3-2001-in sera from Finnish children who had acquired NoV infection. Most of the NoV-infected patients studied here were <2 years of age, in accordance with previous reports demonstrating that the incidence of NoV-associated gastroenteritis peaks in children from 6 to 23 months of age [25, 26, [41] [42] [43] . Antibodies against all NoV genotypes were detected in acute-phase sera, but IgG levels against GII-4 NO were generally the highest, especially among children >2 years old. Norovirus variant GII-4 NO dominated since 2009 in Finland [2, 3] and worldwide [21] . No GI infections among study population were detected, which is congruent with the low prevalence of GI infections reported in Finland [2, 3] and in accordance with the low end point serum titers to GI-3 and GI-1 NoV we observed.
The main objective of the present study was to assess correlation of preexisting serum IgG levels and/or antibody-blocking potential and susceptibility to infection with the predominant GII-4 NO genotype. Significant difference in preexisting GII-4 NO-specific antibody responses was observed when IgG titers of the patients who acquired GII-4 NO infection were compared to IgG titers of patients who acquired other GII genotype infection. Of 16 patients without GII-4 NO infection, 9 had very high preexisting GII-4 NO IgG levels (end point titer, >51 200; GMT, 94 809), whereas all 27 GII-4 NO-infected patients had acute serum GII-4 NO-specific end point titers of <50 000 (GMT, 958). High GII-4 NO-specific titers detected only in acutephase serum from patients without GII-4 NO infection probably reflect the magnitude of the genotype-specific IgG titer that is required to confer protection from natural infection.
A response pattern similar to that seen for GII-4 NO genotype, was observed with the serum IgG titers to the ancestor GII-4-1999 strain. The GII-4-1999-specific response measured was likely contributed by cross-reactive IgG antibodies between GII-4 NO and GII-4-1999 VLPs, which share high sequence homology (93% capsid protein identity, by the Protein Basic Local Alignment Search Tool). Earlier serological studies have also demonstrated cross-reactivity within the genogroup, even after primary infection, in children [44] and adults [30, 31] . When end point titers against GII-12, GI-1, and GI-3 in acute-phase sera were compared, no difference was observed between patients with and those without GII-4 NO infection. The relatively low end point titers against these genotypes are likely due to less extensive circulation in the population and lower cross-reactivity with the predominant GII-4 variant [3, 22, 45] .
Furthermore, the ability of acute-phase serum to block binding of GII-4 NO VLPs to HBGA ligand correlated with homologous type-specific IgG titers. The analysis of paired sera from the study subjects further confirmed positive correlation between the GII-4 NO-specific serum IgG level and homologous blocking potential of the serum. When recently acquired IgG antibody was assessed from convalescent-phase sera, it was observed that all patients seroconverted after GII-4 NO infection, and concurrently, there was 16-256-fold increases in the GII-4 NO-specific BT 90 , compared with acute-phase sera. Taken together, our results show a correlation between a low acute-phase serum GII-4 NO-specific IgG titer (end point titer, ≤12 800) and a low antibody-blocking potential (BT 90 , ≤100) with a high susceptibility to GII-4 NO infection. Congruently, a high specific IgG end point titer and a considerable blocking potential appeared to protect from GII-4 NO infection. In contrast to our results, there are publications showing that high preexisting serum NoV-specific IgG levels measured by ELISA have not been protective from virus challenge in adults [35, 36] . The discrepancies can be partly explained by the fact that not all antibodies detected by ELISA are functional in blocking the binding of the virus to the receptor and thus preventing the infection. We also observed that a high preexisting GII-4 NO antibody titer has not been able to protect children from infection with other circulating GII genotypes-GII.7/GII.6, GII.e/GII.4, GII.b, and GII.g/GII.12-indicating the relevance of strainspecific immunity in protection from NoV infection.
Sera collected from children for prospective epidemiological study give valuable information for elucidating correlates of protection in young populations by defining the magnitude and functionality of preexisting and recently acquired NoV-specific immune responses. Data presented here indicate a positive correlation between high preexisting genotype-specific serum IgG titers and blockade of VLP binding to HBGA receptors to protection from infection, addressing the relevance of serum IgG responses in children. Our results are in concordance with those of earlier studies [22, 23, 32, 33] showing that a low preexisting antibody titer indicates higher risk of developing NoV infection in the near future in children. Our data support the prevailing understanding that induction of broad, high titer serum IgG levels with good blocking potential are necessary for protection from NoV infections.
Notes
